Seer to highlight AI-driven multi-cancer screening and next-generation proteomics at ASMS 2026

Seer, Inc. will showcase its AI-driven multi-cancer screening approach and next-generation proteomics capabilities at at ASMS 2026 in San Diego, USA. Seer and its collaborators will demonstrate how the Proteograph^® Product Suite is enabling deep, unbiased, scalable proteomics with peptide-level precision to uncover hidden biological insights and drive new discoveries across translational and population-scale research.

Expanding adoption of nanoparticle-enabled proteomics

Seer’s presence at ASMS 2026 will include a featured breakfast symposium previewing one of the most ambitious applications of AI-driven proteomics to date, an oral presentation introducing next-generation proteomic data processing tools, and a broad range of customer-led scientific presentations.

Collectively, these sessions highlight the accelerating adoption of nanoparticle-enabled proteomics across translational research, systems biology, biomarker discovery, and precision medicine.

Studies combining this scale and depth were not previously possible before the Proteograph platform and represent a paradigm shift in how proteomics can be applied to human health.

From AI-powered multi-cancer screening with collaborators at Korea University to next-generation data processing infrastructure such as Radiant DIA™, the work being shared at ASMS 2026 underscores both the scientific impact and operational maturity of the Proteograph platform as a foundation for the next generation of biomarker discovery and precision medicine.

Seer breakfast symposium: AI proteomics for multi-cancer screening

ID-free AI Proteomics for Multi-Cancer Screening

Date: Monday, June 1

Time: 7:00 PT

Location: Conference Center, Room 33B

Speakers:

• Dr. Sang-Won Lee, Korea University and TargetX Inc
• Dr. Jaewoo Kang, Korea University and AIGEN Sciences

The symposium will provide the first public preview of findings from Seer’s large-scale collaboration with Korea University, which is analyzing more than 20,000 clinical plasma samples using the Proteograph Product Suite. Drs Lee and Kang will describe how AI-driven analysis of deep, unbiased plasma proteomics can enable highly sensitive, scalable multi-cancer screening, supporting population-scale precision health initiatives.

Seer oral presentation: Building scalable proteomics with Radiant DIA and Fulcrum Pipeline

Building Scalable Proteomics with Radiant DIA™ and the Fulcrum Pipeline™

Date: Tuesday, June 2

Time: 9:50 PT

Location: Ballroom 20BC

Presenter: Seth Just, Data Engineering and Software, Seer

As proteomics studies expand to tens of thousands of samples, data processing has become a rate-limiting step that constrains how quickly results can move from instrument output to biological insight. In this oral presentation, Seer will introduce Radiant DIA, a next-generation data-independent acquisition (DIA) proteomics search engine in development that is designed to deliver an order-of-magnitude reduction in runtime while preserving the depth and sensitivity required for discovery.

Paired with the Fulcrum Pipeline, a modular framework for distributed search and cluster-scale post-processing across local and cloud environments, Radiant DIA aims to remove one of the most significant computational constraints on modern population-scale proteomics. This integrated infrastructure is intended to enable researchers to process the largest cohorts in dramatically less time.

Scientific presentations featuring Seer technology

ASMS 2026 attendees will have access to a diverse set of customer-led presentations enabled by the Proteograph Product Suite. These presentations include development of a Human Blood Proteome (HuBP) database profiling more than 10,000 proteins to advance understanding of human physiology and disease, comparative evaluations of next-generation plasma proteomics workflows and instrumentation platforms, multiomics investigations into Alzheimer’s disease and environmental exposure biology, and studies demonstrating advances in glycoproteomics, extracellular vesicle analysis, and deep plasma proteome characterization.

Together, these sessions underscore the growing adoption of Seer-powered proteomics across translational research, systems biology, biomarker discovery, and precision medicine applications.

Oral presentations

• Integrative Blood Proteomics Reveals the HuBP Atlas of over 10,000 Proteins Informing Human Physiology and Disease. Presenter: Zhenyu Sun | June 1, 10:10 | Room 6A
• Using complementary discovery and targeted proteomic techniques on cerebrospinal fluid (CSF) provides unprecedented insight into Alzheimer’s Disease (AD). Presenter: Lauren Tang | June 1, 16:10 | Ballroom 20A

Workshop session

• Quantitative DIA Data Analysis. Panelist: Seth Just | June 3, 17:45–19:00 | Room 6DE

Poster presentations | June 1

• Multi-faceted Technical Evaluation of Illumina, Olink, and Seer + Orbitrap Astral Zoom for Plasma Proteomics. Presenter: William F. Beimers | Poster MP 596
• Multiomics Mapping of Environmental Exposures to Pathway Perturbation in Alzheimer’s Disease. Presenter: Cassandra G. Kempf | Poster MP 490
• Deep-Visual LC-MS Proteomics of Charcot-Leyden-like Crystallopathy in Fra2 Mice. Presenter: Hendrik Wesseling | Poster MP 634
• MS-Based Proteomic Characterization of the SOD1-G93A Mouse Model. Presenter: Bo Yang | Poster MP 049

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>